Millipore Sigma Vibrant Logo
Attention: We have moved. Merck Millipore products are no longer available for purchase on MerckMillipore.com.Learn More

481981 Nifedipine - CAS 21829-25-4 - Calbiochem

481981
Purchase on Sigma-Aldrich

Aperçu

Replacement Information

Tableau de caractéristiques principal

CAS #Empirical Formula
21829-25-4C₁₇H₁₈N₂O₆

Products

RéférenceConditionnement Qté
481981-250MG Ampoule plast. 250 mg
Description
OverviewRelatively selective blocker of L-type Ca2+ channels. One of the most extensively studied blockers of 1,4-dihydropyridine-type Ca2+ channels, and a pharmacologically-useful vasodilator. Induces apoptosis in human glioblastoma cells.
Catalogue Number481981
Brand Family Calbiochem®
SynonymsL-Type Calcium Channel Blocker III
References
ReferencesReid, K., et al. 1997. J. Pharmacol. Exp. Ther. 283, 993.
Kondo, S., et al. 1995. J. Neurosurg. 82, 469.
Antkiewicz-Michaluk, L., et al. 1994. Eur. J. Pharmacol. 254, 9.
Calabresi, P., et al. 1994. J. Neurosci. 14, 4871.
Akman, M.S., et al. 1993. Endocrinology 132, 1286.
Cirillo, M., et al. 1993. Circ. Res. 72, 847.
Young, R.J., et al. 1993. Biochim. Biophys. Acta 1146, 81.
Janis, R., et al. 1987. Adv. Drug Res. 16, 311.
Product Information
CAS number21829-25-4
ATP CompetitiveN
FormYellow solid
Hill FormulaC₁₇H₁₈N₂O₆
Chemical formulaC₁₇H₁₈N₂O₆
ReversibleN
Structure formula ImageStructure formula Image
Quality LevelMQ100
Applications
Biological Information
Primary TargetL-type Ca2+ channels
Purity≥98% by UV
Physicochemical Information
Cell permeableN
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
RTECSUS7975000
Safety Information
R PhraseR: 22

Harmful if swallowed.
S PhraseS: 36-26

Wear suitable protective clothing.
In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.
Product Usage Statements
Storage and Shipping Information
Ship Code Ambient Temperature Only
Toxicity Harmful & Carcinogenic / Teratogenic
Storage +15°C to +30°C
Protect from Light Protect from light
Do not freeze Ok to freeze
Special InstructionsFollowing reconstitution, refrigerate (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Packaging Information
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Référence GTIN
481981-250MG 04055977183443

Documentation

Nifedipine - CAS 21829-25-4 - Calbiochem FDS

Titre

Fiche de données de sécurité des matériaux (FDS) 

Nifedipine - CAS 21829-25-4 - Calbiochem Certificats d'analyse

TitreNuméro de lot
481981

Références bibliographiques

Aperçu de la référence bibliographique
Reid, K., et al. 1997. J. Pharmacol. Exp. Ther. 283, 993.
Kondo, S., et al. 1995. J. Neurosurg. 82, 469.
Antkiewicz-Michaluk, L., et al. 1994. Eur. J. Pharmacol. 254, 9.
Calabresi, P., et al. 1994. J. Neurosci. 14, 4871.
Akman, M.S., et al. 1993. Endocrinology 132, 1286.
Cirillo, M., et al. 1993. Circ. Res. 72, 847.
Young, R.J., et al. 1993. Biochim. Biophys. Acta 1146, 81.
Janis, R., et al. 1987. Adv. Drug Res. 16, 311.
Fiche technique

Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

Revision15-May-2008 RFH
SynonymsL-Type Calcium Channel Blocker III
DescriptionRelatively selective blocker of L-type Ca2+ channels. One of the most extensively studied Ca2+ channel blockers of 1,4-dihydropyridine-type and a pharmacologically useful vasodilator. Induces apoptosis in human glioblastoma cells.
FormYellow solid
CAS number21829-25-4
RTECSUS7975000
Chemical formulaC₁₇H₁₈N₂O₆
Structure formulaStructure formula
Purity≥98% by UV
SolubilityDMSO or Ethanol
Storage Protect from light
+15°C to +30°C
Do Not Freeze Ok to freeze
Special InstructionsFollowing reconstitution, refrigerate (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Toxicity Harmful & Carcinogenic / Teratogenic
Merck USA index14, 6528
ReferencesReid, K., et al. 1997. J. Pharmacol. Exp. Ther. 283, 993.
Kondo, S., et al. 1995. J. Neurosurg. 82, 469.
Antkiewicz-Michaluk, L., et al. 1994. Eur. J. Pharmacol. 254, 9.
Calabresi, P., et al. 1994. J. Neurosci. 14, 4871.
Akman, M.S., et al. 1993. Endocrinology 132, 1286.
Cirillo, M., et al. 1993. Circ. Res. 72, 847.
Young, R.J., et al. 1993. Biochim. Biophys. Acta 1146, 81.
Janis, R., et al. 1987. Adv. Drug Res. 16, 311.